Date: 2016-03-28
Type of information: Nomination
Compound:
Company: Moderna Therapeutics (USA - MA)
Therapeutic area:
Type agreement: nomination
Action mechanism:
Disease:
Details: * On March 28, 2016, Moderna Therapeutics, a clinical stage pioneer in the development of messenger RNA (mRNA) Therapeutics™, announced that Saqib Islam has been appointed Chief Business Officer, effective May 9th. As a member of the executive leadership team, among Mr. Islam’s areas of focus will be oversight of Moderna’s global strategic planning, corporate development and business development functions. Mr. Islam joins Moderna from Alexion Pharmaceuticals, Inc., where he served as Executive Vice President, Chief Strategy and Portfolio Officer. In that role, he led Alexion’s Corporate Strategy, Corporate Development, Business Development, Enterprise Risk Management, Competitive Intelligence and Corporate Project Management functions and had primary responsibility for executing Alexion’s corporate growth strategies and contributing to its assessment and management of global operations. Previously, Mr. Islam worked for over 20 years in international business management with a focus on business development, strategic decision-making and planning, and capital markets.
Financial terms:
Latest news:
